Celltrion

Celltrion presents new two-year data for subcutaneous infliximab (CT-P13 SC) in inflammatory bowel disease (IBD) at the 19th ECCO Congress

Retrieved on: 
Friday, February 23, 2024
Health, Pharmaceutical, Celltrion, Ulcerative colitis, Week, Crohn's disease, European, Safety, UC, Abstract, Patient, IBD, Congress, ECCO

These data were presented as poster presentations at the 19th European Crohn’s and Colitis Organisation (ECCO) annual congress in Stockholm, Sweden.

Key Points: 
  • These data were presented as poster presentations at the 19th European Crohn’s and Colitis Organisation (ECCO) annual congress in Stockholm, Sweden.
  • The LIBERTY-CD and LIBERTY-UC studies were continued up to 102 weeks as extension phase treatments, building on the initial LIBERTY trials.
  • The two-year studies assessed the long-term efficacy and safety of CT-P13 SC in patients with Crohn's disease (CD) and ulcerative colitis (UC), respectively.
  • “The early observation of mucosal healing at Week 22 showcases the potential of subcutaneous infliximab treatment in improving patient care,” said Nam Lee, Medical Director at Celltrion.

Greg Belinfanti Appointed President of One Equity Partners; Dick Cashin Continues Full-Time Role as Chairman

Retrieved on: 
Tuesday, January 30, 2024
Professional Services, Finance, Multimedia, The arts, Lehman Brothers, Politics, JPMorgan Chase, OneLink, Celltrion, Local Initiatives Support Corporation, EGS, Investment, ArthroCare, Harvard Law School, Investment banking, One Equity Partners, OEP, Culture, Trust, Management

One Equity Partners (“OEP”), a middle-market private equity firm, today announced that Greg Belinfanti has been named President of the firm.

Key Points: 
  • One Equity Partners (“OEP”), a middle-market private equity firm, today announced that Greg Belinfanti has been named President of the firm.
  • He succeeds founder Dick Cashin who will continue to serve as Chairman and play an active, full-time role in managing the firm and its investments.
  • View the full release here: https://www.businesswire.com/news/home/20240130325743/en/
    Greg Belinfanti, President of One Equity Partners (Photo: Business Wire)
    “Greg is an incredibly talented investment professional and a tremendous colleague who leads by example.
  • Prior to joining OEP, Belinfanti served as a Vice President in the Investment Banking division of Lehman Brothers.

Abpro Announces Filing of Registration Statement on Form S-4 in Connection with Business Combination Agreement with Atlantic Coastal Acquisition Corp. II

Retrieved on: 
Monday, January 22, 2024
HER2, Celltrion, VEGF, CD3, Stomach, Research, CSO, Ophthalmology, Partnership, Prospectus, GPC3, Form, ACAB, Hepatocellular carcinoma, Acquisition, Drug development, KRX, Therapy, Register, Breast, Engineering, Vaccine

Upon the closing of the proposed business combination, the combined company is expected to be named “Abpro Corporation” and to list its common stock on Nasdaq under the new ticker symbol “ABP”.

Key Points: 
  • Upon the closing of the proposed business combination, the combined company is expected to be named “Abpro Corporation” and to list its common stock on Nasdaq under the new ticker symbol “ABP”.
  • The proposed business combination sets Abpro’s implied pre-money equity valuation at $500 million.
  • Consistent with the recent signing of the Business Combination Agreement, the Atlantic Coastal and Abpro boards of directors have approved the proposed business combination, which is expected to be completed in the first half of 2024 subject to, among other things, the approval by Atlantic Coastal and Abpro stockholders, and other customary closing conditions.
  • Financial Group, LLC, is serving as financial advisor to Atlantic Coastal.

Celltrion presents strategic vision and growth plan at the 42nd Annual J.P. Morgan Healthcare Conference

Retrieved on: 
Thursday, January 11, 2024
Celltrion, Patient, Health, Intelligence, Biosimilar, PHS, Infliximab, Conference, Drug development, FDA, Pharmaceutical industry

Celltrion's Chairman Jung-Jin Seo and CEO Jin-Seok Seo discussed the company's strategic priorities and progress, including the company's vision to move beyond biosimilars through the 2024 launch of ZYMFENTRA™ in the U.S. and expansion into digital healthcare.

Key Points: 
  • Celltrion's Chairman Jung-Jin Seo and CEO Jin-Seok Seo discussed the company's strategic priorities and progress, including the company's vision to move beyond biosimilars through the 2024 launch of ZYMFENTRA™ in the U.S. and expansion into digital healthcare.
  • He also shared insights and trends on the biosimilar industry and how the market landscape is impacting Celltrion's strategy.
  • Jin-Seok Seo said, ''Celltrion has the potential to grow its revenue by at least fivefold in 2030, once our 22-drug portfolio is commercialized.
  • Celltrion remains committed to pursuing its goal in promoting the health and well-being of patients."

When it Comes to Treating Ulcerative Colitis, US Gastroenterologists May be Betting it All on JAK…

Retrieved on: 
Thursday, November 30, 2023
Marketing, IBD, Failure, Adalimumab, Risankizumab, MOA, Gastroenterology, Physician, Ustekinumab, HCP, Ulcerative colitis, Injection, UC, RealTime, JAK, Patient, Celltrion, Upadacitinib, Pharmaceutical industry

Over the past two months, the landscape of UC treatment has undergone a significant expansion, introducing four new options.

Key Points: 
  • Over the past two months, the landscape of UC treatment has undergone a significant expansion, introducing four new options.
  • The first line of UC treatment remains overwhelmingly dominated by the firmly established anti-TNF therapies (such as Humira and Remicade) alongside Entyvio.
  • Furthermore, the favored choice among physicians in Crohn’s disease (CD), Stelara, has continued to enjoy a position in later-line UC treatment.
  • Patient Chart Dynamix™ is an independent, data-driven service unveiling real patient management patterns through rigorous analysis of large-scale patient chart audits.

US Gastroenterologist Projections Suggest Significant Shift in Ulcerative Colitis Landscape Afoot, with Launches of Eli Lilly's Omvoh, Pfizer's Velsipity, Takeda's Subcutaneous Entyvio, and Celltrion's Zymfentra

Retrieved on: 
Monday, November 13, 2023
HCP, Ustekinumab, Pfizer, Q3, JAK, Takeda, Patient, MOA, AbbVie, Colitis, Ulcerative colitis, Benchmarking, IBD, Launch, Upadacitinib, BMS, S1P, Infliximab, Adalimumab, Gastroenterology, Celltrion, UC, RealTime, Pharmaceutical industry, Tofacitinib, Vedolizumab, Lilly

These additions come amidst an already bustling market, teeming with both branded and increasingly competitive biosimilar alternatives.

Key Points: 
  • These additions come amidst an already bustling market, teeming with both branded and increasingly competitive biosimilar alternatives.
  • However, the influx of innovative agents suggests that upcoming changes are poised to be more substantial and transformative.
  • This extension enjoys the highest pre-launch familiarity and generates significantly higher interest in gaining approval.
  • Although prescribers display significant enthusiasm for Entyvio SC, its anticipated impact on the broader market is projected to be modest.

VEGZELMA® (bevacizumab-adcd) receives preferred formulary status with Ventegra® for commercially insured patients

Retrieved on: 
Monday, December 11, 2023
Urine, Reproduction, Skeleton, Headache, PSA, Kidney, Erythroderma, Patient, Pharmacy, Birth, Nephrotic syndrome, MBA, Cancer, Miscarriage, Safety, Incidence, VTE, Bevacizumab, Corneal opacity, Wound healing, VEGFR2, Gastrointestinal perforation, Hemoptysis, Female, Fetus, CHF, Celltrion, Pharming, Necrotizing fasciitis, Heart failure, Fistula, Risk, Tracheoesophageal fistula, Bleeding, Organogenesis, Partnership, Rhinitis, Hypertension, Primary ovarian insufficiency, Back pain, Pregnancy, Glioblastoma, PRES, Nosebleed, Skull, FDA, ATE, VEGF, MBM, Hypertensive encephalopathy, Toxicity, Nursing, Pharmaceutical industry, Birth control, Dietary supplement, Proteinuria

Ventegra's proprietary formulary program (which includes Formulary Shield and the Ventegra Specialty Inclusion Program) is available for access by more than 400 clients and 13 million members/patients that are enrolled with Ventegra.

Key Points: 
  • Ventegra's proprietary formulary program (which includes Formulary Shield and the Ventegra Specialty Inclusion Program) is available for access by more than 400 clients and 13 million members/patients that are enrolled with Ventegra.
  • Gastrointestinal Perforations and Fistula: Discontinue for gastrointestinal perforations, tracheoesophageal fistula, grade 4 fistula, or fistula formation involving any organ.
  • Surgery and Wound Healing Complications: In patients who experience wound healing complications during VEGZELMA treatment, withhold VEGZELMA until adequate wound healing.
  • Do not administer VEGZELMA for at least 28 days following a major surgery, and until adequate wound healing.

Rani Therapeutics Announces Strategic Program Prioritization, Expansion of Manufacturing and Plans to Streamline Business Operations to Support Near-Term Value Drivers and Long-Term Growth of the RaniPill® Technology Platform; Reports Preliminary Third Qu

Retrieved on: 
Wednesday, November 1, 2023
Osteoporosis, HC, Ustekinumab, Growth, Workforce, Therapy, Celltrion, Patient, Teriparatide, SAN, Pharmaceutical industry, Cryptocurrency

“We are laser-focused on driving forward our key programs to create near-term value and fuel long-term growth.

Key Points: 
  • “We are laser-focused on driving forward our key programs to create near-term value and fuel long-term growth.
  • We are also expanding our manufacturing footprint to support scale for late-stage development and partnering.
  • Rani is also entering into a lease for approximately 33,000 square feet to expand its manufacturing footprint.
  • Rani estimates that cash, cash equivalents and marketable securities will be approximately $60.5 million as of September 30, 2023.

Celltrion USA announces distribution and incorporation of YUFLYMA® (adalimumab-aaty), a Humira® biosimilar, to CarePartners Specialty Pharmacy Cost Savings Programs

Retrieved on: 
Thursday, October 26, 2023
Science, Other Science, Biotechnology, Research, Pharmaceutical, Health, FDA, Clinical Trials, Food, Pharmacist, Celltrion, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Light, Biosimilar, Patient, Generic drug, Pharmaceutical industry, Adalimumab

Celltrion USA, Inc. (Celltrion USA) today announced its FDA-approved biosimilar, YUFLYMA® (adalimumab-aaty), has been added to CarePartners Specialty Pharmacy Cost Savings Programs.

Key Points: 
  • Celltrion USA, Inc. (Celltrion USA) today announced its FDA-approved biosimilar, YUFLYMA® (adalimumab-aaty), has been added to CarePartners Specialty Pharmacy Cost Savings Programs.
  • YUFLYMA is a high-concentration (100mg/mL) and citrate-free formulation of the Humira® (adalimumab) biosimilar.
  • CarePartners and its strategic partners will offer and distribute YUFLYMA as the lowest net cost high-concentration Humira (adalimumab) biosimilar to over 10 million plan members.
  • “Partnering with Celltrion to offer YUFLYMA solidifies our cost saving initiatives for plan sponsors, employers, health plans, and other payers.

Celltrion, Inc. & Celltrion Healthcare Co., Ltd. Announce Shareholders Approval of Merger

Retrieved on: 
Monday, October 23, 2023
Research, Finance, Professional Services, Biotechnology, Health, Pharmaceutical, General Health, Other Professional Services, Science, Retirement, Celltrion, FDA, Treasury, E-GMS, News, Sheraton Grand Incheon Hotel, Canopy Growth, Songdo Convensia, Acquisition, KRW, Multimedia, Pharmaceutical industry, Security (finance), Retail

Celltrion Group announced that the merger agreement between Celltrion, Inc. (KRX:068270) (“Celltrion”) and Celltrion Healthcare Co., Ltd. (KOSDAQ:091990) (“Celltrion Healthcare”) was approved at the extraordinary general meeting of shareholders (“EGM”) of the two companies held at Songdo Convensia and Sheraton Grand Incheon Hotel, respectively, on October 23, 2023.

Key Points: 
  • Celltrion Group announced that the merger agreement between Celltrion, Inc. (KRX:068270) (“Celltrion”) and Celltrion Healthcare Co., Ltd. (KOSDAQ:091990) (“Celltrion Healthcare”) was approved at the extraordinary general meeting of shareholders (“EGM”) of the two companies held at Songdo Convensia and Sheraton Grand Incheon Hotel, respectively, on October 23, 2023.
  • Under the merger plan, Celltrion will merge Celltrion Healthcare and issue Celltrion shares to Celltrion Healthcare shareholders.
  • Celltrion Healthcare shareholders will receive 0.4492620 shares of Celltrion for each Celltrion Healthcare share they own.
  • The merger price per share is KRW 148,853 for Celltrion and KRW 66,874 for Celltrion Healthcare.